Apremilast for immune checkpoint inhibitor-associated psoriasis and psoriatic arthritis: A systematic review

Name: Apremilast for immune checkpoint inhibitor-associated psoriasis and psoriatic arthritis: A systematic review
Creator: Manjit kaur
Published: 2024-11-29T13:49:56.557Z
Keywords: Psoriatic Arthritis, Systematic Review, Psoriasis

kaur, Manjit; Feldman, Anna-Elise; Dulmage, Brittany; Kaffenberger, Jessica; Kaffenberger, Benjamin

doi:10.17632/22frj4rmbz.1

Apremilast for immune checkpoint inhibitor-associated psoriasis and psoriatic arthritis: A systematic review

Published: 29 November 2024| Version 1 | DOI: 10.17632/22frj4rmbz.1

Contributors:

Manjit kaur, Anna-Elise Feldman, Brittany Dulmage, Jessica Kaffenberger, Benjamin Kaffenberger

Description

We conducted a systematic review of Apremilast for treating immune checkpoint inhibitor-associated psoriasis and psoriatic arthritis. Supplementary File 1. Search Strategy and Eligibility Criteria. Supplementary File 2. Complete List of References. Supplementary Table I. List of Included Studies, Characteristics of Psoriasis/Psoriasiform Eruption and Outcome after Apremilast Use. Supplementary Table II & III. Risk of Bias Assessment of Included Studies.

Apremilast for immune checkpoint inhibitor-associated psoriasis and psoriatic arthritis: A systematic review

Description

Files

Categories

Licence